A proprietary combination–phentermine (an appetite suppressant similar to an amphetamine) and topiramate (an anticonvulsant) medication formulated as an extended-release capsule, which is used with diet and exercise to manage obesity in patients with a BMI of 30 or more, or in patients with a BMI of 27 or more and one or more related co-morbidities–hypertension, type 2 diabetes and hypercholesterolaemia.

Adverse effects Paraesthesia, dry mouth, constipation, upper respiratory tract infection, nasopharyngitis, metabolic acidosis, tachycardia, headache. Also, foetal toxicity, suicidal ideation, mood and sleep disorders, cognitive impairment

Contraindications Pregnancy, glaucoma, hyperthyroidism

Proprietary names Qnexa, Vivus 

Reference http://www.drugs.com/qsymia.html

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.